3/13/2013

Pfizer said it would stop developing its midstage hepatitis C drug filibuvir, or PF-00868554. Meanwhile, Gilead Sciences and AbbVie's pipelines include experimental hepatitis C therapies that have shown promise in trials.

Related Summaries